FY2026 EPS Estimates for Opus Genetics Raised by Analyst

Opus Genetics, Inc. (NASDAQ:IRD) – Stock analysts at Lifesci Capital boosted their FY2026 earnings estimates for shares of Opus Genetics in a research note issued on Wednesday, February 25th. Lifesci Capital analyst F. Brisebois now anticipates that the company will earn ($0.45) per share for the year, up from their prior forecast of ($0.48). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share.

A number of other equities research analysts have also issued reports on IRD. B. Riley Financial initiated coverage on Opus Genetics in a research note on Wednesday, December 10th. They set a “buy” rating and a $9.00 price target for the company. Piper Sandler initiated coverage on shares of Opus Genetics in a research note on Tuesday, November 25th. They issued an “overweight” rating and a $7.00 target price on the stock. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a report on Thursday, January 22nd. Finally, Chardan Capital restated a “buy” rating and set a $9.00 price objective on shares of Opus Genetics in a report on Thursday, November 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $7.75.

Opus Genetics Stock Up 15.9%

Shares of NASDAQ:IRD opened at $4.16 on Monday. The firm has a market capitalization of $286.87 million, a PE ratio of -2.21 and a beta of 0.44. The business has a 50 day simple moving average of $2.65 and a two-hundred day simple moving average of $2.09. Opus Genetics has a 1 year low of $0.65 and a 1 year high of $4.17. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.23 and a quick ratio of 1.23.

Insider Activity at Opus Genetics

In other Opus Genetics news, Director Fighting Blindness Foundation sold 4,000,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the completion of the sale, the director owned 5,492,171 shares in the company, valued at $11,808,167.65. This represents a 42.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cam Gallagher bought 83,000 shares of the company’s stock in a transaction on Monday, December 29th. The shares were bought at an average cost of $1.97 per share, for a total transaction of $163,510.00. Following the transaction, the director directly owned 83,000 shares in the company, valued at approximately $163,510. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On Opus Genetics

A number of hedge funds have recently made changes to their positions in the stock. Balyasny Asset Management L.P. bought a new stake in Opus Genetics during the fourth quarter valued at about $5,463,000. BIOS Capital Management LP lifted its position in shares of Opus Genetics by 270.1% during the second quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock valued at $3,462,000 after buying an additional 2,688,180 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Opus Genetics during the fourth quarter valued at about $4,025,000. Nantahala Capital Management LLC boosted its holdings in shares of Opus Genetics by 42.9% in the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after buying an additional 1,435,407 shares in the last quarter. Finally, Mink Brook Asset Management LLC grew its position in shares of Opus Genetics by 34.5% in the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock worth $3,348,000 after buying an additional 427,684 shares during the last quarter. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.